A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...

Rostaporfin is under clinical development by TuHURA Biosciences and currently in Phase III for Metastatic Breast Cancer.

ACTUS-101 is under clinical development by Asklepios BioPharmaceutical and currently in Phase II for Pompe Disease.

GPN Vaccines, formerly GPN Vaccines, is a clinical-stage company focused on creating vaccines that offer robust protection against bacterial pathogens. It develops vaccines to protect adults and ...

EXO-CD24 is under clinical development by Nano24med and currently in Phase II for Acute Respiratory Distress Syndrome.

Amivantamab is under clinical development by Johnson & Johnson and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.

HMBD-001 is under clinical development by Hummingbird Bioscience and currently in Phase I for Pancreatic Ductal Adenocarcinoma.

Zastaprazan is under clinical development by Onconic Therapeutics and currently in Phase III for Gastric Ulcers.

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

Bexotegrast is under clinical development by Pliant Therapeutics and currently in Phase II for Liver Fibrosis.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...